Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Free Cash Flow (2020 - 2025)

Maxcyte (MXCT) has disclosed Free Cash Flow for 6 consecutive years, with -$6.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 7.48% to -$6.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$39.7 million, a 87.11% decrease, with the full-year FY2024 number at -$29.3 million, down 15.26% from a year prior.
  • Free Cash Flow was -$6.2 million for Q3 2025 at Maxcyte, up from -$10.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $6.1 million in Q3 2022 to a low of -$23.7 million in Q4 2022.
  • A 5-year average of -$6.9 million and a median of -$5.9 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: skyrocketed 639.44% in 2021, then tumbled 12172.73% in 2024.
  • Maxcyte's Free Cash Flow stood at $1.5 million in 2021, then tumbled by 1731.44% to -$23.7 million in 2022, then soared by 100.28% to $66000.0 in 2023, then tumbled by 12172.73% to -$8.0 million in 2024, then increased by 21.56% to -$6.2 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Free Cash Flow are -$6.2 million (Q3 2025), -$10.4 million (Q2 2025), and -$15.1 million (Q1 2025).